SEC Tracker
Get the app
HRMY · XBRL financial data

Harmony Biosciences Holdings financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (HRMY's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers160168*155173186201*185200239244*215261
Cost of goods and services sold3243*27324354*32386069*4563
Gross profit128125*127141143147*153162180175*171198
Research and development1730*22642535*35505550*6947
General and administrative2328*26272929*31343058*3328
Total operating expenses6385*751198291*96114114137*134109
Operating income (loss)6540*52216256*56486539*3789
Interest income3———————————
Interest expense75*5444*4444*33
Other income (expense)(0)0*(0)0(0)0*(0)(0)(0)(0)*(0)(0)
Income tax expense (benefit)1313*1310167*12101718*718
Net income (loss)3827*38124649*46405122*3275
Earnings per share, basic USD per share0.640.46*0.680.200.810.87*0.790.690.880.39*0.561.30
Earnings per share, diluted USD per share0.630.45*0.670.200.790.85*0.780.680.870.38*0.551.28
Weighted average shares, basic millions of shares6058*57575757*57575858*5858
Weighted average shares, diluted millions of shares6159*58585858*59585959*5959

Balance sheet

CSV

Fiscal quarters (HRMY's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents325312333317387453489546647753589550
Short-term investments4642393023141819262352118
Accounts receivable6774808382831069310197108111
Inventory556677667556
Total current assets463451480458522579643691839907779814
Property and equipment, net000111111———
Right-of-use asset223322211556
Total assets7788118478589289991,0561,1081,2081,2721,2721,373
Accounts payable71815231114172826182922
Accrued liabilities73999292110121———191150169
Current portion of long-term debt151515151516181920202020
Total current liabilities112164154147161175175180223252217234
Long-term debt182179175171168163158153149144139134
Lease liability, non-current111111100555
Total liabilities296344332320331340335335373401361374
Retained earnings (accumulated deficit)(170)(143)(105)(93)(47)24888138161193269
Total stockholders' equity481467515539597659721773835870910999
Total liabilities and equity7788118478589289991,0561,1081,2081,2721,2721,373
Common shares outstanding (cover page) millions of shares595757575757575858585858

Cash flows

CSV

Fiscal quarters (HRMY's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)3827*38124649*46405122*3275
Stock-based compensation8*9*1011*11*10*1211*11*10*119*
Net cash from operating activities63*77*3143*71*76*3479*109*126*2892*
Purchases of property and equipment0*0*01*0*1*00*0*0*——
Net cash from investing activities(1)*(36)*(6)(55)*1*(7)*2(20)*(5)*(18)*(184)(132)*
Share repurchases—50*——————————
Proceeds from long-term debt—0*——————————
Repayments of long-term debt0*4*44*4*4*44*4*5*55*
Net cash from financing activities(55)*(54)*(4)(3)*(1)*(3)*(0)(3)*(3)*(3)*(7)(1)*
Net change in cash7*(13)*21(16)*70*66*3657*101*106*(163)(40)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Harmony Biosciences Holdings55026192*58.2M— 10-QJun 30, 2026
Travere Therapeutics12422598*96.0M— 10-QSep 30, 2026
Ani Pharmaceuticals36026657*not reported— 10-QJun 30, 2026
Celldex Therapeutics470(57)*78.5M12.5 quarters 10-QJun 30, 2026
Adaptive Biotechnologies17072(6.4)*159.6M53.8 quarters 10-QJun 30, 2026
Innoviva57012052*72.2M— 10-QJun 30, 2026
Arrowhead Pharmaceuticals5575(177)*141.3M9.0 quarters 10-QJun 30, 2026
Mannkind53109(18)*321.5M6.0 quarters 10-QJun 30, 2026
Schrodinger28859(34)*not reported12.1 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.